EXEL - Exelixis Non-GAAP EPS of $0.35 beats by $0.19 revenue of $451.14M beats by $94.19M

Exelixis press release (NASDAQ:EXEL): Q4 Non-GAAP EPS of $0.35 beats by $0.19. Revenue of $451.14M (+67.0% Y/Y) beats by $94.19M. Shares +2.67%. Cabozantinib franchise achieved a significant milestone with $1.08 Billion in U.S. Net Product Revenues for the Full Year 2021, including $302.7 Million for the Fourth Quarter 2021.  Cash, cash equivalents, restricted cash equivalents and investments were $1.9 billion at December 31, 2021, compared to $1.5 billion at December 31, 2020. 2022 Guidance: Total revenues $1.525 billion - $1.625 billion, Net product revenues $1.325 billion - $1.425 billion, Cost of goods sold 5% - 6% of net product revenues.

For further details see:

Exelixis Non-GAAP EPS of $0.35 beats by $0.19, revenue of $451.14M beats by $94.19M